Pear Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pear Therapeutics, Inc.
Pear Therapeutic’s PDTs have a new home at PursueCare thanks to $20m in series B funding led by Tr.X Capital, led by Pear's former CEO.
FDA authorized Better Therapeutics’ AspyreRx, formerly known as BT-001, a prescription-only digital therapeutic that provides cognitive behavioral therapy to adults with type 2 diabetes. The company plans to launch it in the fourth quarter of 2023.
Sofinnova Partners has played an important role in defining the medtech investment space for the past 50 years, helping bring to market a plethora of life-saving technologies, even when they appear, initially, to be risky.
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb and Hannah Daniel discuss highlights from their DTA Summit coverage in Washington. Reed Miller talked to Frank Chan, the president of Medtronic’s Patient Monitoring, about plans for their patient monitoring as an independent company and Bayer AG’s new business unit focusing on digital health.
- Digital Health
- Medical Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.